阿斯利康任命万凌·马泰洛为非执行董事，加入审计委员会

----- a7296s.htm -----
6-K
1
a7296s.htm
DIRECTORATE CHANGE
a7296s
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of September 2026
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Directorate change
1 September 2026
Non-Executive Board Appointment
AstraZeneca PLC announced today that Wan Ling Martello has been
appointed as Non-Executive Director with effect from 1 September
2026.
Wan Ling will become a member of the Audit Committee on appointment
to the Board.
Wan Ling Martello is a founding partner of BayPine, Independent
Director of the Alibaba Group and Director of The Lovesac Company.
Further biographical details are set out below.
Michel Demaré, Chair of AstraZeneca, said "I am delighted that
Wan Ling has accepted our invitation to join the AstraZeneca Board.
Wan Ling's substantial international experience as an executive
leader and as a board member at large global businesses and in
several industries, will undoubtedly bring a valuable contribution
to the Board. Her CFO and digital transformation experience will
have a significant impact on her work on the Audit Committee and
the Board as a whole."
Biographical details - Wan Ling Martello
Wan Ling Martello has spent most of her career leading executive
teams and organisations in the consumer products and retail
industries, and has significant expertise in B2C technology-enabled
business models and digital transformation. She has held senior
leadership roles at Nestlé, Walmart, NCH Marketing Services (a
former subsidiary of Nielsen), Borden Foods and Kraft
Foods.
Among her career highlights, Wan Ling served as Nestlé SA's
global CFO, where she revitalised the global finance organisation,
established a new data-driven resource allocation and portfolio
management framework for the entire company, and led numerous
M&A transactions. She was then appointed as CEO of
Nestlé's Asia, Oceania and Sub-Saharan Africa (AOA) business
and re-focused the entire business on driving growth and using
digital transformation initiatives to drive greater consumer
engagement. Wan Ling is a founding partner of BayPine, a private
equity firm based in Boston, USA.
In addition to her role at BayPine, Wan Ling is an Independent
Director of Alibaba Group, listed on the New York Stock Exchange
and a Director of The Lovesac Company, listed on Nasdaq. From
June 2017 to May 2025, Wan Ling was a director of Uber
Technologies, Inc. (listed on the New York Stock Exchange from May
2019), and from January 2021 to April 2025, Wan Ling was an
independent non-executive director of Stellantis N.V. (listed on
the New York Stock Exchange, Euronext Milan and Euronext Paris).
Wan Ling holds a BS from the University of the Philippines and an
MBA-MIS from the University of Minnesota.
Except as set out above, no disclosure obligations arise under
paragraphs (1) to (6) of UKLR 6.4.8 R of the UK Financial
Conduct Authority's Listing Rules in respect of Wan Ling Martello's
appointment.
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit
astrazeneca.com
and
follow the Company on Social Media
@AstraZeneca
.
Contacts
For details on how to contact the Investor Relations Team, please
click
here
.
For Media contacts, click
here
.
Matthew Bowden
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
AstraZeneca
PLC
Date:
01 September 2026
By: /s/
Matthew Bowden
Name:
Matthew Bowden
Title:
Company Secretary